Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study
Status
Conditions
Treatments
Details and patient eligibility
About
The project will investigate the modulation of flavin-containing monooxygenase (FMO) formation of the CVD risk factor trimethylamine-N-oxide (TMAO) in patients with kidney disease.
Full description
Twelve patients with stage 3 to 4 kidney disease will receive an intervention for four weeks and a matching placebo in a crossover study design. Reduction of serum TMAO from baseline to end of intervention will be the primary endpoint.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Male or female subjects 18 years of age, but not more than 75 years of age at the time of enrollment.
- Must be able to provide signed and dated informed consent.
- Medical diagnosis of chronic kidney disease (eGFR ≤ 60 ml/min/1.73m2 )
Exclusion criteria
-
Vital signs outside of acceptable range at Screening Visit
-
Use of any of the following drugs within the last 3 months:
Systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular, or oral); oral, intravenous, intramuscular, nasal or inhaled corticosteroids; cytokines; methotrexate or immunosuppressive cytotoxic agents; anti-diarrheal agents, bile acid sequestrants.
-
Consuming commercial probiotics including tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component. Ordinary dietary components such as fermented beverages/milks, yogurts, foods do not apply.
-
Chronic, clinically significant hepatic abnormality (i.e. elevated 3X ULN ALT/AST), as determined by medical history or physical examination.
-
History of cancer except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision.
-
Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet.
-
Recent history of chronic alcohol consumption defined as more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day.
-
Any confirmed or suspected condition/state of immunosuppression or immunodeficiency.
-
History of active uncontrolled gastrointestinal disorders or diseases including: Inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis; irritable bowel syndrome (IBS) (moderate-severe); persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated); chronic constipation. Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time.
-
Patient who may be pregnant or lactating.
-
Not willing to abstain from cruciferous vegetable (i.e. cabbage, brussels sprouts, garden cress, mustard greens, turnips, broccoli, collard greens , cauliflower, kale) consumption.
-
Current smoking.
-
Unwilling or unable to adhere to study procedures or instructions.
-
Patients taking any of the following medications, methimazole, alosetron, duloxetine, ramelteon, tasimelteon, theophylline, tizanidine, clozapine, pirfenidone and ramosetron.
-
Allergies to corn or soy.
Trial design
Primary purpose
Allocation
Interventional model
Masking
13 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal